Methods: ADAPT-DES was a prospective, multicenter, real-world registry of 8,583 pts at 11 international centers undergoing percutaneous coronary intervention (PCI) with DES designed to determine the frequency, timing, and correlates (clinical, angiographic and platelet reactivity) of early and late ST. In a pre-specified IVUS substudy, outcomes were examined according to IVUS vs. angiographic guidance. We herein report the 2-year clinical results. Results: Average pt age was 64.0 years, and 74.1% were male. During the index procedure, IVUS guidance was used in 3,361 (39.2%) of procedures. Pts in the IVUSguided group were more likely to present with an acute coronary syndrome and have higher platelet reactivity on clopidogrel (PRU>208), and were treated with longer and larger stents. At 2-year follow-up, definite/probable ST occurred in 22 (0.7%) pts in the IVUS-guidance group vs 71 (1.4%) pts in the angiography-guidance group (P¼0.002; Table). In a propensity adjusted multivariable model, IVUS guidance was independently associated with a reduced 2-year rate of ST (HR [95%CI] ¼ 0.43 [0.25, 0.74], p¼0.002), myocardial infarction (MI; 0.65 [0.51, 0.83], p¼0.0006), clinically driven target lesion target revascularization (TLR; 0.77 [0.62, 0.96], p¼0.02) and target vessel revascularization (TVR; 0.83 [0.70, 0.97], p¼0.02), and all-cause death/ MI (0.72 [0.61, 0.85], p¼0.0001).
Background: The current study compared the novel Biotronik Osiro stent, eluting sirolimus from a biodegradable polymer PLLA, applied to the surface of a thin-strut (60 mm) Silicon-Carbide coated Cobalt-Chromium stent with the Abbot Xience PrimeÔ stent. The aim was to compare the neointimal hyperplasia, stent apposition and stent strut coverage at 9 months after procedure using IVUS and OCT imaging techniques. Methods: We performed a prospective, multicenter, randomized controlled study (RCT) in 452 subjects (63.4AE10.0 yrs) with symptomatic coronary artery disease due to de novo stenotic lesions in native coronary arteries with a reference vessel diameter ! 2.25 mm and 4.0 mm and a lesion length 26 mm. The study is registered at clinicaltrials.gov (NCT01356888). Subjects were randomly assigned (2:1) to receive the Osiro SES or the Xience PrimeÔ EES. In pre-specified cohort sizes, the enrolled subjects were invited to participate in either the IVUS (N¼66) or the OCT (N¼65) sub studies. All subjects were enrolled between July 5, 2011 -Jan 10, 2012. The IVUS endpoints were neointimal hyperplasia and stent apposition at 9 months after procedure. The OCT endpoints were neointimal hyperplasia, stent apposition and stent strut coverage at 9 months. Baseline and 9 month follow-up images were analyzed by independent and blinded core laboratories; IVUS by Medstar, US and OCT by Cardialysis, NL. Results: IVUS and OCT confirmed complete and a non-significant difference in apposition in both cohorts (OCT P¼0.624 and IVUS P¼0.325). IVUS and OCT confirmed less neointimal hyperplasia area at 9-months in the Osiro cohort (OCT P¼0.024 and IVUS P¼0.043). The Osiro cohort had a higher strut coverage and lower strut-neointima thickness at 9 months, confirmed by OCT (coverage P¼0.042 and thickness P<0.001). Conclusions: In this RCT, the Osiro SES with a biodegradable polymer showed comparable stent and strut apposition to the Xience PrimeÔ EES with a durable polymer. The Osiro had a statistically significant lower neointimal area in both the IVUS and OCT sub studies. OCT analysis of the strut level confirmed that both the neointima thickness and percent coverage was significantly better in the Osiro cohort.
TCT-70
Ability of the bioresorbable vascular scaffold to re-cap the underlying plaque. A serial optical coherence tomography study Background: The objective of this study is to examine the phenotypic changes of the superficial plaque occurring follow an Absorb bioresorbable vascular scaffold (Absorb BVS) implantation. Methods: Forty six patients (47 lesions) who underwent Absorb BVS implantation and had serial optical coherence tomographic evaluation at baseline, and at any follow-up time point (6 months, 1 year, 2 years or 3 years) were included in the current analysis. Two observers identified thin capped fibroatheromas (TCFA) in the scaffolded and native segments that were located proximally or distally to the scaffolded segment, marked the circumferential location of the TCFA and of the calcific tissues and measured the thickness of the developed neointima at follow-up. These data were used to construct spread-out vessel plots that portrayed the spatial location of the detected tissues and their extent was expressed as percentage of the endoluminal vessel wall surface. Results: Twelve TCFA were detected at baseline in the scaffolded segments and all were covered at follow-up. On the other hand most of the TCFA identified in native segments (6 out of 10) did not change their phenotype at follow-up. The amount of the superficial lipid core remained unchanged at follow-up in the spread-out vessel plots in both the scaffolded (4.90AE10.12% at baseline vs. 4.18AE10.84%, at follow-up, P¼0.388) and native segments (28.47AE20.87% at baseline vs. 28.12AE22.00%, at follow-up, P¼0.767). There was no difference in the thickness of the neointima developed over TCFA and calcific spots in scaffolded segments at follow-up (mean thickness over TCFA: 223AE83mm vs. 213AE88mm over calcific spots, P¼0.687). Conclusions: Our results demonstrate that the neointimal tissue developed after Absorb BVS implantation shields equally both lipid and calcific tissues. Thus, the Absorb BVS could be considered as a potential useful device for the invasive recapping of high risk plaques.
TCT-71
The Background: The morphological assessment of neointimal tissue using optical coherence tomography (OCT) is highly significant to clarify the pathophysiology of in-stent restenosis (ISR) lesions. These OCT findings may be related to recurrence of ISR. The aim of this study was to define the impact of OCT findings on recurrence of ISR after various types of percutaneous coronary intervention (PCI) including plain . The morphological assessment of neointimal tissue at the minimum lumen area site as to restenotic tissue structure (homogeneous, heterogeneous, or layered type) using OCT was performed. We examined the association between tissue structure and mid-term (6-8 months) results including ISR and target lesion revascularization (TLR) rates. Results: The patients were 263 men and 58 women, and the mean age was 68.9AE9.6 years. The mean follow-up period was 209AE38 days. The association of tissue structure with ISR and TLR rates in each groups is shown in the figure. The ISR rates of lesions with homogeneous and layered structure were significantly lower in the PCB and DES groups than in the POBA group, whereas there were no differences between 3 groups in heterogeneous structure.
Conclusions:
The morphological assessment of ISR tissue using OCT might suggest favorable types of PCI for ISR lesions. Background: Previous IVUS studies, due to small size, were not able to establish a relation between statin use and its impact on plaque composition by grayscale and VH-IVUS. Methods: ADAPT-DES was a prospective multicenter study of 8,583 pts undergoing percutaneous coronary intervention (PCI) using drug-eluting stents. A pre-specified grayscale and VH-IVUS sub-study enrolled 2,064 pts. Pre-PCI imaging of 773 pts identified 907 culprit lesions. Pts with vs without statin use prior to hospital admission were compared. Results: Overall, 43.6% (377) of pts were treated with statins prior to admission. Pts using statins were older and had a higher prevalence of risk factors such as diabetes (33% vs 20%, p<0.0001), hypertension (90% vs 59%, p¼0.02), and renal insufficiency (creatinine clearance <60 ml/min, 14% vs 7%, p¼0.001). At admission, statin pts were frequently taking medications such as aspirin, ACEI/ARB, and beta-blockers (all p<0.0001). Statin pts were more likely to present with more stable angina, while non-statin pts more frequently presented with ST-segment elevation (STE) and non-STE acute coronary syndromes (Table) . Statin pts were more likely to have angiographic 3-vessel disease and calcification. Grayscale and VH-IVUS findings showed that statin pts had slightly larger minimum lumen area (MLA) along with less plaque burden, but with more dense calcium (DC). Statin pts had more calcified thick-cap fibroatheromas (ThCFA: necrotic core >10%, confluent DC >10%, well-defined fibrous cap), but fewer thin-cap fibroatheromas (TCFAs) or plaque ruptures.
Conclusions: Chronic statin use in PCI patients was associated with more stable clinical presentation and IVUS findings consistent with greater lesion stability (fewer VH-TCFAs and plaque ruptures, more ThCFAs) compared to pts with CAD who were not taking statins.
TCT-73
Forward-Looking IVUS: Technology Overview and First-in-human Case Review Background: Chronic total occlusions of the vessels in the periphery are often encountered and present significant technical challenges. The presence of occlusive disease is associated with higher rates of failed re-canalization and worse long term results. Currently, subintimal dissection and re-entry techniques are commonly used to treat these challenging lesions. For all subsequent therapy, including angioplasty, stenting and atherectomy, the ability to cross occlusions while staying within the true lumen is preferred. Devices and techniques which allow recanalization through the true lumen represent an important and unmet clinical need. Forward-looking IVUS (FL.IVUS) is a new technology that has been developed to provide real-time therapy guidance while crossing challenging peripheral occlusions. Methods: A non-randomized, non-blinded, multi-center, first-in-man, four-phase, prospective study was performed to assess the safety and feasibility of the Forwardlooking IVUS system in subjects with peripheral artery disease undergoing endovascular therapy. In the fourth phase of this study, the FL.IVUS device was used to provide real-time guidance while crossing CTOs in iliac and femoral vessels. Results: Twenty cases were completed at three centers to assess the safety and feasibility of the Forward-looking IVUS system in crossing peripheral chronic total occlusions. The FL.IVUS catheter provided real-time images of the vessel and occlusion. These images were used for guidewire placement and to confirm true lumen position while crossing the CTOs. Two cases from the first-in-human series will be presented to highlight the clinical utility and imaging performance of the FL.IVUS system. Conclusions: A novel Forward-looking IVUS device was used to provide real-time, intraluminal guidance for the treatment of CTOs in the iliac and femoral arteries. This first-in-human clinical series demonstrates the preliminary safety and feasibility of this novel imaging modality for the endovascular treatment of complex peripheral artery disease. Future directions for the technology include improved catheter performance and new imaging and software features.
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